Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: A case report and literature review of the evidence for use of these Kampo herbal formulae

Neuropsychiatric Disease and Treatment

Volumn 9, Issue 1, 2012, Pages 151-155

  Okamoto, Hideki ^a   Chino, Atsushi ^a   Hirasaki, Yoshiro ^a   Ueda, Keigo ^a   Iyo, Masaomi ^a   Namiki, Takao ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aggressiveness; Intermittent explosive disorder; Tardive dystonia; Traditional medicine

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; KAMPO; METHAMPHETAMINE; NEUROLEPTIC AGENT; OLANZAPINE; ORENGEDOKU TO; RISPERIDONE; TIZANIDINE; UNCLASSIFIED DRUG; YOKUKAN SAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AGGRESSION; ALZHEIMER DISEASE; ARTICLE; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; CASE REPORT; CLINICAL GLOBAL IMPRESSION SCALE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GOITER; HUMAN; IMPULSIVENESS; INTERMITTENT EXPLOSIVE DISORDER; IRRITABILITY; LOW DRUG DOSE; MALE; PSYCHOSIS; SOMNOLENCE; TARDIVE DYSTONIA; TRADITIONAL MEDICINE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VIOLENCE;

EID: 84872848303     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S38318     Document Type: Article

References (14)

1. de Caires S, Steenkamp V. Use of Yokukansan (TJ-54) in the treatment of neurological disorders: a review. Phytother Res. 2010;24(9): 1265-1270.
2. Miyaoka T, Furuya M, Yasuda H, etal. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study. Clin Neuropharmacol. 2009;32(1):6-9.
3. Miyaoka T, Furuya M, Yasuda H, etal. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):761-764.
4. Miyaoka T, Furuya M, Yasuda H, Hayashia M, Inagaki T, Horiguchi J. Yi-gan san for the treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1): 150-154.
5. Satoh T, Takahashi T, Iwasaki K, etal. Traditional Chinese medicine on four patients with Huntington's disease. Mov Disord. 2009;24(3): 453-455.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV; Fourth Edition. Arlington, VA: American Psychiatric Association; 1994.
7. Okamoto H. Reconsideration of Japanese traditional herbal medicine: new field of research and clinical medicine. Mini Rev Med Chem. 2006;6(5):543-547.
8. The Japan Society for Oriental Medicine. Introduction to Kampo: Japanese Traditional Medicine. Tokyo: Elsevier Japan; 2005.
9. Terasawa K. Kampo. Tokyo: Standard McIntyre; 1993.
10. Ohta Y, Kobayashi T, Nishida K, Sasaki E, Ishiguro I. Preventive effect of Oren-gedoku-to (Huanglian-Jie-Du-Tang) extract on the development of stress-induced acute gastric mucosal lesions in rats. J Ethnopharmacol. 1999;67(3):377-384.
11. Monji A, Takita M, Samejima T, etal. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):308-311.
12. Hayashi Y, Ishida Y, Inoue T, etal. Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):541-545.
13. Okahara K, Ishida Y, Hayashi Y, etal. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):532-536.
14. Yu CJ, Zheng MF, Kuang CX, Huang WD, Yang Q. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro. J Alzheimers Dis. 2010;22(1):257-266.